Peripheral arterial disease with chronic kidney disease
Conditions
Interventions
Treatment with Kremezin (6g/day) for 12 month
Sponsors
Shonan Kamakura General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) CKD: CKD stage G3a - G5 2) PAD: Fontaine classification I - II 3) Age 20 - 85 years old at the time of consent to participate in the study 4) Outpatient 5) Patients who have personally and voluntarily provided written informed consent, after having received and thoroughly understood an adequate explanation about participation in the study
Exclusion criteria
Exclusion criteria: 1) Patients with diabetes 2) Patients who have newly taken NSAIDs during this study 3) Patients who have taken iodinated contrast medium or gadolinium contrast medium during entry period 4) Patients with major limb amputation 5) Patients with prior stroke and/or prior coronary artery disease 6) Patients with coronary stent by arteriosclerosis 7) Patients who have gastrointestinal obstruction 8) Patients who in currently pregnant, parturient, breast-feeding, or plan to become pregnant during the study period 9) Patients who are judged unsuitable for this study by the doctor in charge of the patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CAVI(Cardio-ankle vascular index) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Renal function: 1/sCr, eGFR 2) Marker: IS, FGF-23 3) Vascular function: PDMP, %FMD, ABI, SPP 4) Diagnostic imaging: pACS 5) Insulin resistance: HOMA-R 6) Safety: Adverse effect | — |
Countries
Japan
Contacts
Public ContactTomoko Machida
Mirai Iryo Research Center Inc, Clinical Research Promotion Dept.
Outcome results
None listed